103 related articles for article (PubMed ID: 1355585)
1. Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial.
Pollak M; Gallant K; Poisson R; Harris A
Metabolism; 1992 Sep; 41(9 Suppl 2):119-20. PubMed ID: 1355585
[TBL] [Abstract][Full Text] [Related]
2. The potential role of somatostatin analogues in breast cancer treatment.
Pollak M
Yale J Biol Med; 1997; 70(5-6):535-9. PubMed ID: 9825480
[TBL] [Abstract][Full Text] [Related]
3. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
Bontenbal M; Foekens JA; Lamberts SW; de Jong FH; van Putten WL; Braun HJ; Burghouts JT; van der Linden GH; Klijn JG
Br J Cancer; 1998; 77(1):115-22. PubMed ID: 9459155
[TBL] [Abstract][Full Text] [Related]
4. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
[TBL] [Abstract][Full Text] [Related]
5. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
6. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro.
Weckbecker G; Liu R; Tolcsvai L; Bruns C
Cancer Res; 1992 Sep; 52(18):4973-8. PubMed ID: 1325289
[TBL] [Abstract][Full Text] [Related]
8. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma.
Vainas G; Pasaitou V; Galaktidou G; Maris K; Christodoulou K; Constantinidis C; Kortsaris AH
J Exp Clin Cancer Res; 1997 Mar; 16(1):119-26. PubMed ID: 9148872
[TBL] [Abstract][Full Text] [Related]
9. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
Esposito V; Esposito D; Lo Iudice G
Minerva Endocrinol; 2001 Dec; 26(4):289-92. PubMed ID: 11782718
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin and growth hormone regulation in cancer.
Manni A
Biotherapy; 1992; 4(1):31-6. PubMed ID: 1347453
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of diabetic retinopathy with somatostatin analogues].
Lang GE
Ophthalmologe; 2004 Mar; 101(3):290-3. PubMed ID: 15007609
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin and somatostatin analogues in human breast carcinoma.
Prévost G; Israel L
Recent Results Cancer Res; 1993; 129():63-70. PubMed ID: 8102489
[No Abstract] [Full Text] [Related]
13. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly.
Colao A; Auriemma RS; Pivonello R; Kasuki L; Gadelha MR
Pituitary; 2016 Jun; 19(3):235-47. PubMed ID: 26519143
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.
O'Byrne KJ; Dobbs N; Propper DJ; Braybrooke JP; Koukourakis MI; Mitchell K; Woodhull J; Talbot DC; Schally AV; Harris AL
Br J Cancer; 1999 Mar; 79(9-10):1413-8. PubMed ID: 10188884
[TBL] [Abstract][Full Text] [Related]
15. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
[TBL] [Abstract][Full Text] [Related]
16. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
[TBL] [Abstract][Full Text] [Related]
17. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels.
Canobbio L; Cannata D; Miglietta L; Boccardo F
Anticancer Res; 1995; 15(6B):2687-90. PubMed ID: 8669848
[TBL] [Abstract][Full Text] [Related]
18. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
19. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
Losa M; Mortini P; Giovanelli M
Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362
[TBL] [Abstract][Full Text] [Related]
20. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
